Somatropin for short stature

Record ID 32018005326
Authors' objectives: What are the evidence-based guidelines regarding the use of growth hormone therapy for children with Short Stature Secondary to Small for Gestational Age?What are the evidence-based guidelines regarding the use of growth hormone therapy for children with Idiopathic Short Stature?
Authors' results and conclusions: · For children with short stature who were born small for gestational age, 1 guideline suggests increasing human growth hormone dose when treatment response is unsatisfactory, while aiming for normal insulin-like growth factor 1 levels. · For children with idiopathic short stature, 1 guideline recommends against the routine use of growth hormone. It suggests initiating growth hormone therapy on a case-by-case basis, with a starting dose ranging from 0.24 mg/kg/week to 0.47 mg/kg/week, as well as conducting an assessment 12 months after initiation to optimize dosage. · The development of recommendations from guidelines included in this report was challenged by limited relevant evidence, as well as heterogeneity of growth hormone dose and frequency and treatment response found in available literature. Future guidelines should also consider patient perspectives, resource implications, and the facilitators of and barriers to therapy within the context of health care systems in Canada.
Project Status: Completed
Year Published: 2023
English language abstract: An English language summary is available
Publication Type: Rapid Review
Country: Canada
MeSH Terms
  • Growth
  • Growth and Development
  • Growth Disorders
  • Body Height
  • Human Growth Hormone
  • Short Stature Homeobox Protein
Organisation Name: Canadian Agency for Drugs and Technologies in Health
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
Contact Email:
Copyright: <p>Canadian Agency for Drugs and Technologies in Health (CADTH)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.